These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 33748145)

  • 1. m6A Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer.
    Zhao H; Xu Y; Xie Y; Zhang L; Gao M; Li S; Wang F
    Front Cell Dev Biol; 2021; 9():650023. PubMed ID: 33748145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma.
    Zhang T; Sheng P; Jiang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):2805-2822. PubMed ID: 35780396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma.
    Zhang Y; Li L; Ye Z; Zhang L; Yao N; Gai L
    Ann Transl Med; 2021 Oct; 9(20):1554. PubMed ID: 34790760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers.
    Li R; Yin YH; Ji XL; Liu X; Li JP; Qu YQ
    Front Mol Biosci; 2021; 8():644620. PubMed ID: 34150845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of RNA N6-methyladenosine in primary Sjögren's syndrome.
    Xiao Q; Wu X; Deng C; Zhao L; Peng L; Zhou J; Zhang W; Zhao Y; Fei Y
    Front Med (Lausanne); 2022; 9():959388. PubMed ID: 36465909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer.
    Jiang T; Xing L; Zhao L; Ye Z; Yu D; Lin S
    BMC Med Genomics; 2023 May; 16(1):105. PubMed ID: 37194014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constructing and validating of m6a-related genes prognostic signature for stomach adenocarcinoma and immune infiltration: Potential biomarkers for predicting the overall survival.
    Yang J; Wu Z; Wu X; Chen S; Xia X; Zeng J
    Front Oncol; 2022; 12():1050288. PubMed ID: 36620557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment.
    Deng X; Sun X; Hu Z; Wu Y; Zhou C; Sun J; Gao X; Huang Y
    FASEB J; 2023 Sep; 37(9):e23155. PubMed ID: 37606566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal genetic and epigenetic patterns of m6A regulators associated with tumor microenvironment in colorectal cancer.
    Ren S; Xiao Y; Wang H; Zhao L; Li H; Wei L; Huang Y; Liu H
    Transl Cancer Res; 2023 Aug; 12(8):2033-2047. PubMed ID: 37701104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinformatics analysis of the correlation between m6A RNA methylation regulators and the immune infiltration and prognosis of bladder cancer.
    Wu J; Wang X; Xu H; Tian J; Ji H; Zhu J; Guo H; Chen Z
    Ann Transl Med; 2022 Dec; 10(24):1386. PubMed ID: 36660722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and Validation of an m6A RNA Methylation Regulators-Based Prognostic Signature for Esophageal Cancer.
    Xu LC; Pan JX; Pan HD
    Cancer Manag Res; 2020; 12():5385-5394. PubMed ID: 32753956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic and transcriptomic alterations in m6A regulatory genes are associated with tumorigenesis and poor prognosis in head and neck squamous cell carcinoma.
    Paramasivam A; George R; Priyadharsini JV
    Am J Cancer Res; 2021; 11(7):3688-3697. PubMed ID: 34354868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC.
    Cheng W; Li M; Zhang L; Zhou C; Yu S; Peng X; Zhang W; Zhang W
    Front Pharmacol; 2022; 13():973116. PubMed ID: 36120320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of n6-methyladenosine (m6A) regulators and role of FTO/TNC in scleroderma.
    Yu Y; Liang C; Tang Q; Shi Y; Shen L
    Gene; 2024 Feb; 894():147989. PubMed ID: 37972699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
    Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
    Front Genet; 2022; 13():872186. PubMed ID: 35937991
    [No Abstract]   [Full Text] [Related]  

  • 17. m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocarcinoma.
    Li F; Wang H; Huang H; Zhang L; Wang D; Wan Y
    Front Genet; 2020; 11():994. PubMed ID: 33193582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis.
    Zhao Z; Cai Q; Zhang P; He B; Peng X; Tu G; Peng W; Wang L; Yu F; Wang X
    Front Mol Biosci; 2021; 8():657087. PubMed ID: 34179079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NME6 as a potential biomarker and therapeutic target involved in immune infiltration for lung adenocarcinoma.
    Luo L; Li Y; Zhang L; Yang L
    Technol Health Care; 2024; 32(4):2277-2291. PubMed ID: 38517815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expressions of m6A RNA methylation regulators and their clinical predictive value in cervical squamous cell carcinoma and endometrial adenocarcinoma.
    Wu H; Dong H; Fu Y; Tang Y; Dai M; Chen Y; Wang G; Wu Y
    Clin Exp Pharmacol Physiol; 2021 Feb; 48(2):270-278. PubMed ID: 33006785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.